Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
25.61
+0.12 (0.47%)
At close: Jul 10, 2025, 4:00 PM
26.12
+0.51 (1.99%)
After-hours: Jul 10, 2025, 5:17 PM EDT

Janux Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
9.3410.598.088.613.64-
Upgrade
Revenue Growth (YoY)
28.12%30.99%-6.14%136.79%--
Upgrade
Cost of Revenue
79.3768.3954.9253.4426.243.04
Upgrade
Gross Profit
-70.04-57.8-46.84-44.83-22.6-3.04
Upgrade
Selling, General & Admin
43.5541.0526.1422.2610.331.8
Upgrade
Operating Expenses
43.5541.0526.1422.2610.331.8
Upgrade
Operating Income
-113.58-98.85-72.98-67.09-32.93-4.84
Upgrade
Interest Expense
------0.21
Upgrade
Interest & Investment Income
35.8429.8514.694.030.26-
Upgrade
EBT Excluding Unusual Items
-77.74-68.99-58.29-63.06-32.67-5.05
Upgrade
Other Unusual Items
------1.74
Upgrade
Pretax Income
-77.74-68.99-58.29-63.06-32.67-6.78
Upgrade
Net Income
-77.74-68.99-58.29-63.06-32.67-6.78
Upgrade
Net Income to Common
-77.74-68.99-58.29-63.06-32.67-6.78
Upgrade
Shares Outstanding (Basic)
57544441241
Upgrade
Shares Outstanding (Diluted)
57544441241
Upgrade
Shares Change (YoY)
24.21%22.12%6.14%76.24%2471.20%36.71%
Upgrade
EPS (Basic)
-1.37-1.28-1.32-1.52-1.39-7.41
Upgrade
EPS (Diluted)
-1.37-1.28-1.32-1.52-1.39-7.41
Upgrade
Free Cash Flow
-46.53-44.17-52.43-49.37-18.46-4.37
Upgrade
Free Cash Flow Per Share
-0.82-0.82-1.19-1.19-0.78-4.77
Upgrade
Operating Margin
-1216.61%-933.58%-902.87%-779.04%-905.39%-
Upgrade
Profit Margin
-832.71%-651.62%-721.18%-732.22%-898.32%-
Upgrade
Free Cash Flow Margin
-498.44%-417.20%-648.58%-573.24%-507.51%-
Upgrade
EBITDA
-111.54-96.79-71.02-66.25-32.82-4.83
Upgrade
D&A For EBITDA
2.052.061.960.840.110.01
Upgrade
EBIT
-113.58-98.85-72.98-67.09-32.93-4.84
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q